In advanced NSCLC patients, using smears as a main source for molecular testing and CB for histotype definition and for ALK, ROS1 and PD‐L1 assessment may represent a wise way of handling EBUS neoplastic specimens.24 Here, ALK is linked to non-small cell lung carcinoma.